Pharmacology of Antifungal Drugs

Introduction/Overview

Fungal pathogens represent a significant source of morbidity and mortality across diverse patient populations, ranging from immunocompetent individuals with superficial infections to immunocompromised patients suffering from invasive candidiasis and aspergillosis. The expanding spectrum of antifungal therapy has been driven by the emergence of resistant organisms, advances in drug design, and a deeper understanding of fungal biology. Consequently, a comprehensive grasp of antifungal pharmacology is essential for clinicians, pharmacists, and researchers engaged in the management of fungal diseases.

Clinically relevant antifungal agents are categorized by their chemical structure, mechanism of action, and therapeutic spectrum. Each class exhibits distinct pharmacokinetic profiles, therapeutic indications, and safety concerns, necessitating careful selection and monitoring. The impact of antifungal therapy on patient outcomes is mediated through a combination of drug–pathogen interactions, host factors, and the pharmacologic properties of the agents themselves.

Learning objectives for this monograph include:

• To delineate the principal classes of antifungal drugs and their chemical classifications.
• To describe the pharmacodynamic mechanisms underlying antifungal activity.
• To summarize key pharmacokinetic parameters influencing dosing strategies.
• To identify approved clinical indications and common off‑label uses.
• To recognize major adverse effects and drug interactions pertinent to antifungal therapy.
• To evaluate special considerations in pregnancy, lactation, pediatrics, geriatrics, and organ dysfunction.

Classification

Drug Classes and Categories

Antifungal agents are traditionally grouped into five major classes based on their chemical structure and primary mechanism of action: azoles, polyenes, echinocandins, allylamines, and the newer class of orotomides. Within these categories, sub‑classes further refine therapeutic options.

• Azoles – 5‐α‑dihydroxy steroidal analogues (imidazoles) and triazoles; examples include fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole.
• Polyenes – Macrolide antibiotics that bind ergosterol; amphotericin B (deoxycholate and lipid formulations) and nystatin.
• Echinocandins – β‑1,3‑D‑glucan synthase inhibitors; caspofungin, micafungin, and anidulafungin.
• Allylamines – 5‑chloro‑N‑[1‑(2‑chloro‑2‑oxo‑ethyl)‑2‑methyl‑2‑(4‑chlorophenyl)‑1,3‑dioxol‑4‑yl]‑1‑(2‑methyl‑4‑pyridyl)-2‑(trifluoromethyl)‑1H‑1,3,4‑triazole; terbinafine and naftifine.
• Orotomides – Oral antifungal agent interfering with ergosterol synthesis; VT-1025 (orotomide).

Chemical Classification

From a structural standpoint, antifungal drugs are identified by functional groups that dictate their physicochemical properties and tissue distribution. For instance, azoles possess a heterocyclic ring with a nitrogen atom capable of binding to the heme iron of cytochrome P450 14α‑sterol demethylase, thereby inhibiting ergosterol synthesis. Polyenes contain a long conjugated polyene chain that facilitates binding to ergosterol, forming ion channels. Echinocandins are cyclic lipopeptides, while allylamines are small aliphatic molecules that inhibit squalene epoxidase.

Mechanism of Action

Azoles

Azoles exert their antifungal effect by competitively inhibiting the 14α‑sterol demethylase enzyme, a key component of the ergosterol biosynthetic pathway. The inhibition of this enzyme leads to accumulation of toxic 14‑α‑methylated lanosterol intermediates and depletion of ergosterol, an essential component of fungal cell membranes. The resulting disruption in membrane fluidity and integrity impairs cellular functions such as nutrient transport, pH regulation, and organelle organization. Because the target enzyme is absent in mammalian cells, azoles demonstrate a high degree of selectivity, although hepatic P450 inhibition can occur at therapeutic concentrations, contributing to drug–drug interactions.

Polyenes

Polyenes are amphipathic molecules that bind with high affinity to ergosterol, forming transmembrane pores or channels. This pore formation results in leakage of essential intracellular ions and molecules, culminating in cell lysis. The direct interaction of polyenes with ergosterol accounts for both their potent fungicidal activity and their inherent nephrotoxicity, as off‑target binding to cholesterol can occur in renal tubular cells.

Echinocandins

Echinocandins inhibit β‑1,3‑D‑glucan synthase, an enzyme complex responsible for the synthesis of β‑1,3‑D‑glucan, a critical structural component of the fungal cell wall. By disrupting cell wall integrity, echinocandins exert a fungicidal effect against Candida and Aspergillus species, while exhibiting limited activity against molds such as Cryptococcus. The absence of β‑1,3‑D‑glucan synthase in mammalian cells underlies the favorable safety profile of echinocandins.

Allylamines

Allylamines inhibit squalene epoxidase, an enzyme that catalyzes the oxidation of squalene to 2,3‑oxidosqualene, a precursor of lanosterol. The blockade of this step results in accumulation of squalene and depletion of lanosterol and downstream ergosterol. The mechanism is distinct from that of azoles, reducing cross‑resistance in certain fungal species. Clinical use is predominantly limited to dermatophyte infections due to poor systemic absorption.

Orotomides

Orotomides are prodrugs that undergo hepatic conversion to a metabolite that selectively inhibits fungal 14α‑sterol demethylase. Their unique lipophilicity facilitates effective penetration of the blood–brain barrier, offering potential advantages in central nervous system infections. The selective inhibition mitigates host toxicity, although hepatic metabolism can still lead to drug interactions.

Pharmacokinetics

Absorption

Oral absorption varies markedly among classes. Fluconazole demonstrates high bioavailability (~90%) and rapid absorption. Itraconazole requires acidic conditions and a food meal for optimal absorption, whereas voriconazole displays moderate bioavailability (~60%) with significant first‑pass metabolism. Posaconazole and isavuconazole have improved formulations (oral suspension and tablet, respectively) that enhance absorption across a broader pH range. Polyenes are generally not orally available; amphotericin B deoxycholate is administered intravenously, whereas lipid formulations maintain high plasma concentrations with reduced nephrotoxicity. Echinocandins are available only for intravenous use, with absorption limited to the parenteral route. Allylamines such as terbinafine exhibit excellent oral bioavailability but are predominantly metabolized in the liver. VT‑1025 shows high oral bioavailability and extensive tissue distribution, including the central nervous system.

Distribution

Distribution is influenced by protein binding, lipophilicity, and tissue affinity. Azoles are extensively protein‑bound (>90%) and distribute widely, achieving therapeutic concentrations in the cerebrospinal fluid (CSF) for lipophilic agents such as voriconazole and isavuconazole. Amphotericin B binds extensively to renal tissue, contributing to nephrotoxicity, but also accumulates in the lung, liver, and spleen. Echinocandins exhibit moderate protein binding (~10–30%) and are predominantly distributed within the vascular compartment; they achieve limited penetration into the CSF. Allylamines concentrate in keratinized tissues, explaining their efficacy against dermatophytes. VT‑1025 demonstrates pronounced penetration across the blood–brain barrier, with CSF concentrations approximating 30% of plasma levels.

Metabolism

Metabolic pathways differ across classes. Azoles are primarily metabolized via hepatic cytochrome P450 enzymes (CYP3A4, CYP2C19, CYP2C9). Fluconazole undergoes minimal metabolism; itraconazole is extensively metabolized to hydroxy‑itraconazole. Voriconazole is metabolized by CYP2C19 and CYP3A4, with extensive inter‑individual variability. Posaconazole and isavuconazole are metabolized by glucuronidation and CYP3A4. Amphotericin B is not metabolized and is eliminated unchanged. Echinocandins are metabolized by hydrolytic enzymes and conjugation, with minimal involvement of CYP enzymes. Allylamines are metabolized via hepatic oxidation; terbinafine undergoes extensive first‑pass metabolism. VT‑1025 is metabolized to an active metabolite via hepatic CYP3A4.

Excretion

Renal excretion is the primary route for most azoles, with fluconazole being eliminated unchanged by the kidneys. Voriconazole and isavuconazole undergo renal excretion of both parent drug and metabolites. Posaconazole is predominantly excreted via feces. Amphotericin B is not excreted renally, but nephrotoxicity arises from direct tubular toxicity. Echinocandins are eliminated via hepatic metabolism and biliary excretion. Allylamines are excreted primarily in the urine, with terbinafine metabolites appearing in bile. VT‑1025 metabolites are excreted through both renal and hepatic routes.

Half‑Life and Dosing Considerations

Half‑life (t_1/2) ranges from 2–20 hours for azoles, 11–35 hours for echinocandins, and 1–2 hours for amphotericin B deoxycholate. Dosing regimens are adjusted based on therapeutic drug monitoring, renal function, and drug interactions. For example, voriconazole dosing requires adjustment in patients with hepatic impairment due to CYP2C19 polymorphisms. Echinocandins necessitate loading doses for Candida infections to achieve target trough concentrations. Lipid formulations of amphotericin B allow for higher dosing with reduced nephrotoxicity, but careful monitoring of serum creatinine remains essential.

Therapeutic Uses/Clinical Applications

Approved Indications

Azoles are first‑line agents for candidemia, esophageal candidiasis, and prophylaxis in neutropenic patients. Voriconazole is the preferred treatment for invasive aspergillosis and is indicated for mucormycosis in combination therapy. Posaconazole serves as prophylaxis for high‑risk patients and treatment of refractory mucormycosis. Isavuconazole is recommended for invasive aspergillosis and mucormycosis. Echinocandins are indicated for candidemia, esophageal candidiasis, and intraabdominal candidiasis. Amphotericin B remains the drug of choice for cryptococcal meningitis and severe systemic fungal infections. Allylamines are indicated for onychomycosis and tinea pedis. VT‑1025 is currently approved for invasive mucormycosis and is under investigation for other indications.

Off‑Label Uses

Off‑label applications include fluconazole for histoplasmosis, itraconazole for blastomycosis, and voriconazole for chronic pulmonary aspergillosis. Echinocandins are employed in salvage therapy for refractory fungal infections, and amphotericin B deoxycholate is used for visceral leishmaniasis. Allylamines are occasionally prescribed for tinea corporis. VT‑1025 has shown promise in pilot studies for invasive aspergillosis and fungal keratitis.

Adverse Effects

Common Side Effects

Azoles frequently cause gastrointestinal disturbances (nausea, vomiting) and hepatotoxicity, which may manifest as elevated alanine aminotransferase (ALT) or as a cholestatic pattern. Voriconazole may induce visual disturbances and photosensitivity. Posaconazole can cause nausea and abdominal pain. Isavuconazole is associated with decreased platelet counts and mild elevations in bilirubin. Echinocandins are generally well tolerated but may lead to infusion reactions and transient increases in liver enzymes. Amphotericin B deoxycholate is notorious for nephrotoxicity, electrolyte disturbances (hypokalemia, hypomagnesemia), and infusion-related fever and chills. Allylamines may produce hepatotoxicity and skin rash. VT‑1025 has been associated with mild transaminase elevations and fatigue.

Serious or Rare Adverse Reactions

Azoles can precipitate QT prolongation, particularly when combined with other QT‑prolonging agents. Voriconazole may cause severe hepatotoxicity and neurotoxicity (confusion, hallucinations). Posaconazole can induce severe hepatotoxicity and has been implicated in rare cases of interstitial nephritis. Isavuconazole is associated with rare cases of serious hypersensitivity reactions. Echinocandins may provoke anaphylactoid reactions in rare instances. Amphotericin B deoxycholate is linked to acute tubular necrosis and arrhythmias. Allylamines can cause severe liver injury in susceptible individuals. VT‑1025 has not demonstrated significant serious adverse events in early trials, but long‑term safety remains under investigation.

Black Box Warnings

Amphotericin B deoxycholate carries a black box warning regarding nephrotoxicity and infusion‑related reactions. Voriconazole includes a warning for hepatotoxicity and visual disturbances. The other agents lack formal black box warnings but require vigilance for hepatotoxicity and drug interactions.

Drug Interactions

Major Drug–Drug Interactions

Azoles are potent inhibitors or inducers of CYP3A4, leading to altered plasma levels of concomitant medications such as statins, benzodiazepines, and anticoagulants. Voriconazole is a strong CYP2C19 inhibitor, affecting clopidogrel activation. Posaconazole interacts with drugs eliminated via CYP3A4, including tacrolimus. Isavuconazole has a moderate interaction profile with CYP3A4 substrates (e.g., midazolam). Echinocandins have minimal CYP interactions but may affect the metabolism of drugs eliminated via glucuronidation. Amphotericin B deoxycholate can enhance nephrotoxicity when combined with other nephrotoxic agents (e.g., aminoglycosides). Allylamines may elevate plasma levels of drugs metabolized by CYP2C9. VT‑1025, as a CYP3A4 substrate, may have interactions with strong CYP3A4 inhibitors or inducers.

Contraindications

Azoles are contraindicated in severe hepatic failure due to accumulation of metabolites. Voriconazole is contraindicated in patients with severe hepatic dysfunction (Child‑Pugh class C). Posaconazole is contraindicated in patients with significant drug–drug interactions that cannot be managed. Isavuconazole should be avoided in patients with known hypersensitivity to the drug. Echinocandins are contraindicated in patients with severe hypersensitivity to the drug or its excipients. Amphotericin B deoxycholate is contraindicated in patients with pre‑existing renal failure. Allylamines should not be used in patients with severe hepatic impairment. VT‑1025 contraindications remain to be fully defined, but caution is advised in patients with significant hepatic dysfunction.

Special Considerations

Pregnancy and Lactation

Azoles are classified as category C; however, data suggest that fluconazole is relatively safe for short‑term use, whereas prolonged exposure may increase teratogenic risk. Voriconazole and posaconazole are category D, with potential for fetal harm. Isavuconazole is category C, but limited evidence exists. Echinocandins are category C but have minimal placental transfer; they are considered safe in pregnancy. Amphotericin B deoxycholate is category C but has a favorable safety profile. Allylamines are category C, with limited data. VT‑1025 has insufficient data to define pregnancy category; it is not recommended during pregnancy or lactation. Lactation remains controversial; all antifungal agents are excreted into breast milk in varying amounts, and infant exposure should be considered.

Pediatric Considerations

Dosing in pediatrics requires weight‑based calculations and adjustment for maturation of hepatic enzymes. Fluconazole dosing is 6–12 mg/kg/day, while voriconazole requires loading and maintenance doses based on pharmacokinetic modeling. Posaconazole dosing in neonates is limited; higher clearance necessitates increased doses. Echinocandins are dosed at 0.75–1.5 mg/kg/day for micafungin and 0.5 mg/kg/day for caspofungin. Amphotericin B deoxycholate requires careful monitoring of renal function. Allylamines have limited pediatric use due to poor systemic absorption. VT‑1025 is under investigation in pediatric populations.

Geriatric Considerations

Age‑related decline in hepatic and renal function may necessitate dose reduction. Pharmacodynamic changes include altered protein binding and increased susceptibility to adverse effects such as hepatotoxicity and nephrotoxicity. Polypharmacy increases the risk of drug interactions. Monitoring of liver function tests, renal parameters, and therapeutic drug levels is advised.

Renal and Hepatic Impairment

Renal impairment requires adjustment for azoles cleared renally; fluconazole dosing may be reduced by 50% in severe renal dysfunction. Posaconazole is not recommended in patients with creatinine clearance <30 mL/min. Echinocandins require dose adjustment for hepatic impairment. Amphotericin B deoxycholate is contraindicated in severe renal failure. Allylamines are contraindicated in severe hepatic disease due to increased risk of hepatotoxicity. VT‑1025 dosing adjustments in hepatic or renal impairment are pending further study.

Summary/Key Points

• Antifungal agents are categorized into azoles, polyenes, echinocandins, allylamines, and orotomides, each with distinct mechanisms of action and pharmacokinetic profiles.
• Azoles inhibit ergosterol synthesis via 14α‑sterol demethylase; polyenes bind ergosterol forming membrane pores; echinocandins block β‑1,3‑D‑glucan synthase; allylamines suppress squalene epoxidase; orotomides selectively inhibit fungal demethylase.
• Therapeutic selection depends on infection site, pathogen susceptibility, patient comorbidities, and potential drug interactions.
• Adverse effect profiles range from hepatotoxicity and nephrotoxicity to QT prolongation and infusion reactions; vigilant monitoring is essential.
• Special patient populations—including pregnant, lactating, pediatric, geriatric, and those with organ dysfunction—require individualized dosing strategies and monitoring.
• Ongoing research into novel agents such as orotomides expands the therapeutic arsenal and may address emerging resistance patterns.

In summary, a nuanced understanding of antifungal pharmacology, encompassing mechanisms of action, pharmacokinetics, therapeutic indications, safety considerations, and drug interactions, is indispensable for the effective and safe management of fungal infections in diverse patient populations.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.